Actively Recruiting
Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)
Led by RenJi Hospital · Updated on 2025-10-03
10000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to create a combined cohort platform called SMILE, focused on the relationship between sarcopenia, metabolic diseases, and aging progression. Sarcopenia is an age-related condition involving loss of muscle mass and strength, which increases risks such as falls, disability, and mortality. The study explores how sarcopenia and metabolic disorders together speed up aging and raise risks of cardiovascular events and death. The study collects and integrates various types of data including demographic details, lifestyle factors, clinical symptoms, lab tests, medical imaging, and biospecimens. It uses both past and ongoing participant data to observe health changes over time and study interactions between sarcopenia and metabolic diseases. This longitudinal approach helps identify early changes and risk factors related to aging and disease progression. Participants will be followed over several years with assessments at 5 and 10 years to measure outcomes such as all-cause mortality, cause-specific mortality, and major cardiovascular events. The study involves collecting health information and monitoring participants without any treatment interventions. The findings aim to support precision health strategies to delay functional decline and improve management of aging-related conditions, helping reduce chronic disease risks and economic burden.
CONDITIONS
Brief Title
Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 and over
You will not qualify if you...
- Does not cooperate in signing the informed consent form
- Does not possess legal capacity
- In a state of loss of consciousness
- Suffering from severe mental illness, unable to communicate normally
- The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants undergo collection of multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens to assess sarcopenia and metabolic health.
1 baseline visit (in-person)
Duration - Up to 10 years
Participants are followed longitudinally to track health data and outcomes related to sarcopenia, metabolic diseases, cardiovascular events, and mortality.
Follow-up visits at 5 and 10 years
Trial Site Locations
Total: 1 location
1
Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shanghai, China
Actively Recruiting
Research Team
融
融 黄, Ph.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here